| Title |
Delivery of bevacizumab by intracranial injection: assessment in glioma model
|
|---|---|
| Published in |
OncoTargets and therapy, May 2018
|
| DOI | 10.2147/ott.s159913 |
| Pubmed ID | |
| Authors |
Yu-Xiao Liu, Wen-Jia Liu, Hui-Ru Zhang, Zhi-Wen Zhang |
| Abstract |
Many reports have indicated that the intravenous administration of bevacizumab produces a number of systemic side effects. Therefore, we investigated the therapeutic effects of intratumoral bevacizumab administration using a glioma animal model. The glioma cell lines U251 and U87 that carried luciferase were implanted into the brains of mice to develop glioma models. Glioma-bearing mice were treated with bevacizumab intravenously or intratumorally by Alzet micro-osmotic pumps, and the survival time of mice was monitored. Tumor volumes and location were observed by fluorescence imaging and histological analysis. Levels of microvessel marker, cancer stem cell marker as well as angiogenesis-, invasion-, and inflammation-related factors in tumors were examined by immunohistochemical staining. Mice treated with intratumoral low-dose bevacizumab had smaller tumor volumes, longer survival time, lower microvessel density, and fewer cancer stem cells as compared with untreated and intravenously treated mice. Furthermore, expression levels of inflammation-related factors increased signifiwhereas that of angiogenesis- and invasion-related factors decreased in intratumorally treated animals, compared with intravenously treated mice. These results implied bevacizumab delivery by intratumoral injection via Alzet micro-osmotic pumps may be a more effective and safer protocol for treating gliomas. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 20 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 3 | 15% |
| Student > Master | 3 | 15% |
| Researcher | 3 | 15% |
| Student > Ph. D. Student | 3 | 15% |
| Student > Doctoral Student | 2 | 10% |
| Other | 3 | 15% |
| Unknown | 3 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 4 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 10% |
| Medicine and Dentistry | 2 | 10% |
| Veterinary Science and Veterinary Medicine | 1 | 5% |
| Unspecified | 1 | 5% |
| Other | 4 | 20% |
| Unknown | 6 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 396. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 May 2020.
All research outputs
#76,296
of 25,382,440 outputs
Outputs from OncoTargets and therapy
#3
of 3,016 outputs
Outputs of similar age
#1,821
of 339,234 outputs
Outputs of similar age from OncoTargets and therapy
#1
of 95 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 339,234 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.